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Parasitic diseases cause ~500,000 deaths annually and remain a major challenge for therapeutic devel-
opment. Using a rational design based approach, we developed peptide inhibitors with anti-parasitic
activity that were derived from the sequences of parasite scaffold proteins LACK (Leishmania's recep-
tor for activated C-kinase) and TRACK (Trypanosoma receptor for activated C-kinase). We hypothesized
that sequences in LACK and TRACK that are conserved in the parasites, but not in the mammalian
ortholog, RACK (Receptor for activated C-kinase), may be interaction sites for signaling proteins that are
critical for the parasites' viability. One of these peptides exhibited leishmanicidal and trypanocidal ac-
tivity in culture. Moreover, in infected mice, this peptide was also effective in reducing parasitemia and
increasing survival without toxic effects. The identiﬁed peptide is a promising new anti-parasitic drug
lead, as its unique features may limit toxicity and drug-resistance, thus overcoming central limitations of
most anti-parasitic drugs.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Leishmaniasis is one of the most neglected tropical diseases in
terms of drug discovery and development. In over 88 countries,
Leishmania threatens millions of the poorest people, especially
those living in rural areas. Up to two million people are infected
with Leishmania each year, and 70% of those who die from leish-
maniasis are children (Chappuis et al., 2007). Leishmania donovaniLtd on behalf of Australian Society f(L. donovani) causes visceral leishmaniasis (VL), the most severe
form of the disease in humans (Hotez et al., 2007). Leishmania
amazonensis (L. amazonensis) causes cutaneous leishmaniasis (CL),
the most common form of leishmaniasis in the New World
(Guimaraes-Costa et al., 2009). CL is endemic in 82 countries, with
an incidence of approximately 1.5 million cases per year.
Available treatments for VL and CL include Amphotericin B (a
toxin that forms pores in membranes with some preferences for
ergosterol (Croft et al., 2006)), with some success on the Indian
subcontinent (Chappuis et al., 2007). In contrast to India, the use of
Amphotericin B for VL in East Africa generally results in less-
effective responses; thus, in this region, pentavalent antimonials,
such as sodium stibogluconate (mode of action is not clearlyor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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treatment. However, these drugs are highly toxic and cause serious
side effects including hypotension, seizures, disturbances in cardiac
conduction, and phlebotoxicity (vein inﬂammation, which limits
repeated dosing (Croft and Coombs, 2003)). Moreover, widespread
resistance has developed to these drugs. In March 2014, the FDA
approved miltefosine (developed in the late 1980s for cancer
treatment (Vincent et al., 2014)) for treatment of CL and VL caused
by speciﬁc Leishmania species. Although initially miltefosine
demonstrated high efﬁcacy for VL in India, numerous clinical fail-
ures have since been reported. In addition, only moderate efﬁcacy
has been observed in East Africa and the NewWorld (Monge-Maillo
and Lopez-Velez, 2015).
Trypanosoma cruzi (T. cruzi) infection causes Chagas disease,
affecting ~10 million people in the Americas, and is responsible for
12,000 deaths yearly (Bonney, 2014). Moreover, increased migra-
tion has disseminated this disease worldwide (Bonney, 2014), and
about 70 million people, the majority of which are children, remain
at high risk for contracting this disease (Hotez et al., 2012). During
the acute phase after T. cruzi infection, clinical signs are usually
quite minimal; however, many years after the primary infection,
about 30e40% of infected individuals develop the symptomatic
chronic phase of Chagas disease, characterized by the presence of
myocarditis and heart failure (Garcia et al., 2005). The drugs used to
treat Chagas disease, benznidazole (which causes double-stranded
breaks in DNA (Viotti et al., 2009)) and nifurtimox (mechanism of
action is not yet fully elucidated), have limited use, as they have
severe side effects and exhibit inadequate efﬁcacy in the chronic
stage (Maya et al., 2007). Several clinical studies found that
although benznidazole treatment is somewhat beneﬁcial, its side
effects are still an issue (e.g. clinical study, NCT01162967, in which
the treatment of 20% of the patients in the benznidazole group was
discontinued because of severe cutaneous reactions (Molina et al.,
2014)). Therefore, novel and simple strategies are needed for
developing therapeutic agents that are effective and less toxic, do
not trigger resistance, and are affordable for the infected pop-
ulations in the developing world.
Here, we describe our effort to develop novel inhibitors for the
parasites Leishmania sp. and T. cruzi. We concentrated on generating
inhibitors that are speciﬁc for the parasites by targeting unique
domains of parasite scaffold proteins, LACK (Leishmania's receptor
for activated C-kinase) and TRACK (Trypanosoma receptor for
activated C-kinase).
LACK is a scaffold protein required for the viability of the para-
site and for its establishment in the host (Gomez-Arreaza et al.,
2011). LACK plays an important role in the early phase of Leish-
mania infection (Mougneau et al., 1995); LACK-deﬁcient parasites
are not viable (Kelly et al., 2003), and parasites expressing lower
levels of LACK fail to parasitize even immune-compromised mice
(Kelly et al., 2003). Similarly, TRACK in Trypanosoma is an essential
protein and its homologs are found in several trypanosomatids,
including T. cruzi (Rothberg et al., 2006). Although there is limited
information about TRACK's functions in T. cruzi, in Trypanosoma
brucei (T. brucei), TRACK is expressed throughout the parasite's life
cycle and has a role in the ﬁnal stages of mitosis (Rothberg et al.,
2006). In addition, decreased TRACK expression by RNAi leads to
incomplete cytokinesis in pro-cyclic blood stream trypanosomes
and accelerates the elimination of parasites from peripheral blood
(Rothberg et al., 2006). These data suggest that LACK and TRACK are
involved in essential parasite processes and could be important
anti-parasitic drug targets.
Previously we developed a rational approach to generate in-
hibitors of scaffold proteins, which interfere with normal and
pathological signaling events in cells, in animal models, and in
humans (review (Churchill et al., 2009; Mochly-Rosen and Qvit,2010; Qvit and Mochly-Rosen, 2010)). Relevant to this study, we
have identiﬁed peptides that inhibit the function of RACK (receptor
for activated C-kinase), the mammalian homolog of LACK and
TRACK. RACK is a ubiquitous and highly conserved scaffold protein
(McCahill et al., 2002) that binds several signaling enzymes, all of
which are critical for cell survival, growth, and differentiation
(Schechtman and Moshly-Rosen, 2001). We rationally designed
peptides that interfere with RACK function; these peptides were
found to be effective and selective in cells, in vivo (in a variety of
animal models of human diseases (Inagaki et al., 2003; Kim et al.,
2008)), and in clinical trials (Bates et al., 2008).
Here we apply the same rational design for development of
peptides that target leishmaniasis and Chagas disease. We describe
an inexpensive and fast approach that enabled the identiﬁcation of
novel peptides derived from the parasitic scaffold proteins, LACK
and TRACK, as anti-parasitic therapeutic leads. These may ulti-
mately provide the basis for a speciﬁc, less toxic, and more
convenient treatment for people who suffer from these diseases.
2. Materials and methods
2.1. Sequence alignments
Sequences from different species were aligned using the
following proteins: human RACK (P63244), L. donovani LACK
(Q76LS6), Leishmania braziliensis LACK (A4HGX7), Leishmania pan-
amensis LACK (Q9GUB0), Leishmania major LACK (Q253306),
Leishmania turanica LACK (496205235), Leishmania aethiopica LACK
(496205233), Leishmania tropica LACK (404515577), Leishmania
gerbilli LACK (388850676), Leishmania infantum LACK (P62884),
Leishmania chagasi LACK (P62884), Leishmania mexicana LACK
(Q7KFG4), L. amazonensis LACK (Q95NJ3), Trypanosoma cruzi TRACK
(Q4DTN2), Trypanosoma brucei TRACK (P69103), Trypanosoma
congolense TRACK (O96653), Trypanosoma carassii TRACK (A6ZIC2)
and Trypanosoma vivax TRACK (O96654). The alignment was done
using the FASTA server of the University of Virginia (Pearson and
Lipman, 1988), where: (:) represents identical amino acids, and (.)
represents similar amino acids.
2.2. Peptide synthesis
In brief: Peptides were synthesized on solid support using a fully
automated microwave peptide synthesizer (Liberty, CEM Corpora-
tion). The peptides were synthesized by SPPS (solid phase peptide
synthesis) methodology (Merriﬁeld, 1963) with a ﬂuo-
renylmethoxycarbonyl (Fmoc)/tert-butyl (tBu) protocol. The lysine
side chain was protected with N-methyltrityl (Mtt), a protection
group that can be deprotected selectively using acid labile condi-
tions (Aletras et al., 1995). After completion of the synthesis of the
linear peptide, an anhydride spacer was coupled to the N-terminal
amino group and cyclization was performed using amide bonds
between the moiety linker at the backbone N-terminus and an
epsilon amino on the side chain of a C-terminal Lys residue (Gilon
et al., 1991; Qvit, 2011, 2014). The ﬁnal cleavage and side chain
deprotection was done manually without microwave energy. Pep-
tides were analyzed by analytical reverse-phase high-pressure
liquid chromatography (RP-HPLC) (Shimadzu, MD, USA) and
matrix-assisted laser desorption/ionization (MALDI) mass spec-
trometry (MS) and puriﬁed by preparative RP-HPLC (Shimadzu,
MD, USA).
Further details: All commercially available solvents and reagents
were used without further puriﬁcation. Dichloromethane (DCM),
N-methyl-2-pyrrolidone (NMP), triisopropylsilane (TIS), N,N-
diisopropylethylamine (DIEA), O-benzotriazole-N,N,N0,N0-tetra-
methyl-uronium-hexaﬂuoro-phosphate (HBTU), 1-
N. Qvit et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 74e8476hydroxybenzotriazole (HOBt) and triﬂuoroacetic acid (TFA) were
purchased from SigmaeAldrich (MO, USA); dimethylformamide
(DMF) was purchased from Alfa Aesar (MA, USA); piperidine was
purchased from Anaspec (CA, USA); rink amide AM resin was
purchased from CBL Biopharma LLC (substitution 0.49 mmol/g, CO,
USA); Fmoc-protected amino acids were purchased from Advanced
ChemTech and GL Biochem (KY, USA and Shanghai, China). Side
chains of the amino acids used in the synthesis were protected as
follows: Boc (Lys/Trp), But (Ser/Thr/Tyr), OBut (Asp/Glu), Pbf (Arg),
Mtt (Lys) and Trt (Asn/Cys/Gln/His).
Peptides were chemically synthesized using Liberty Microwave
Peptide Synthesizer (CEM Corporation, Matthews, NC, USA) on
solid support with an additional module of Discover (CEM Corpo-
ration, Matthews, NC, USA) equipped with ﬁber-optic temperature
probe for controlling the microwave power delivery following the
ﬂuorenylmethoxycarbonyl (Fmoc)/tert-butyl (tBu) method in a
30 ml teﬂon reaction vessel. Each deprotection and coupling reac-
tionwas performed with microwave energy and nitrogen bubbling.
Fmoc deprotection was performed in two steps: 30 s and 180 s,
both at 45 W, 75 C using piperidine (20%) in DMF with HOBt
(0.1 M) solution. Coupling reactions were performed by repetition
of the following cycle conditions: 300 s, 25 W, 75 C, with HBTU
(0.11 M) in DMF, amino acids (0.12 M) in DMF and DIEA (0.25 M) in
NMP solution. The coupling and Fmoc deprotection steps were
monitored using Kaiser (ninhydrin) Test (Kaiser et al., 1970) and
small cleavage. Anhydride coupling was carried out as follows:
300 s, 25 W, 75 C, using 10:10:1 anhydride/Di-
isopropylethylamine (DIEA)/4-dimethylaminopyridine (DMAP) in
NMP. Mtt deprotection was carried out using 1:5:94 TFA/TIS/DCM.
Cyclizationwas performed in dibromomethane (DBM) (300 s, 25W,
75 C, using 5:10 benzotriazole-1-yl-oxy-tris-pyrrolidino-phos-
phonium hexaﬂuorophosphate (PyBOP)/Di-isopropylethylamine
(DIEA)). Peptide cleavage from the resin and deprotection of the
amino acid side chains were carried out with TFA/TIS/H2O/phenol
solution (90:2.5:2.5:5 v/v/v/w) for 3 h at room temperature
without microwave energy. The crude products were precipitated
with diethyl ether, collected by centrifugation, dissolved in H2O/
CH3CN and lyophilized.
Products were analyzed by analytical reverse-phase high-pres-
sure liquid chromatography (RP-HPLC) (Shimadzu LC-20 equipped
with: CBM-20A system controller, SPD-20A detector, CTO-20A
column oven, 2  LC-20AD solvent delivery unit, SIL-20AC auto-
sampler, DGU-20A5 degasser from Shimadzu, MD, USA) using an
ultra 120 5 mmC18Q (4.6 mm ID 150 mm) column (Peeke Scientiﬁc,
CA, USA) at 1 mL/min. The solvent systems used were A (H2O with
0.1% TFA) and B (CH3CNwith 0.1% TFA). A linear gradient of 5e50% B
in 15 min was applied and the detection was at 215 nm.
The synthesis products were puriﬁed by preparative RP-HPLC
(Shimadzu LC-20 equipped with: CBM-20A system controller,
SPD-20A detector, CTO-20A column oven, 2  LC-6AD solvent de-
livery unit and FRC-10A fraction collector from Shimadzu, MD,
USA), using an XBridge Prep OBD C18 5 mm (19 mm  150 mm)
column (Waters, MA, USA) at 10 mL/min. The solvent systems used
were A (H2O with 0.1% TFA) and B (CH3CN with 0.1% TFA). For
separation, a linear gradient of 5e50% B in 45 min was applied and
the detection was at 215 nm.
Peptides were conjugated to TAT47-57 (YGRKKRRQRRR) carrier
peptide through an amide bond and with different spacers, as part
of the solid phase peptide synthesis. Note that TAT47-57-based de-
livery of a variety of peptide cargoes into cells has been used now
for over 25 years and delivery of the cargo across biological
membranes and into subcellular organelles has been conﬁrmed
(Begley et al., 2004; Lonn and Dowdy, 2015; Rizzuti et al., 2015).
Furthermore, TAT47-57 and other cell-penetrating peptides have
also successfully been used to deliver cargos into severalintracellular parasites (Corradin et al., 2002; Dhawan et al., 2003).
2.3. Peptide stability
The stability of the peptides was determined by HPLC using
trypsin, which cleaves peptide bonds after lysine and arginine.
Peptide (1 mg/mL, 400 mL) was dissolved in NH4HCO3 buffer (pH
8.0, 200mM), andwasmixedwith a trypsin solution (1 mL,1 mg/mL
in NH4HCO3, pH 8.0) (Promega, WI, USA). The peptide was incu-
bated at 37 C, and samples (100 mL) were taken after 20 min, and
every hour. A solution of 2% TFA and 5% ACN in water (100 mL) was
added, and the samples were analyzed by HPLC and MS (Pakkala
et al., 2007).
2.4. Leishmania donovani promastigote viability in culture assay
To evaluate the bioactivity of the peptides, logarithmic phase L.
donovani promastigote forms (Daah/Dhgprt/Dxprt) were seeded in
96-well microtiter plates at 20,000 cells/100 ml in Dulbecco's
Modiﬁed Eagle's Medium (DMEM, Life Technologies, NY, USA)
media. Promastigotes parasites were incubated with or without
peptides (1, 5, 10, 25, 50, 75 and 100 mM) and the culture was
incubated for 24 h at 26 C. The viability of parasites was assessed
by adding 20 ml of the vital dye Alamar blue (Fisher Scientiﬁc,
Ottawa, ON) to each well and cultures were incubated for an
additional 24 h at 26 C; the reduction of Alamar blue was deter-
mined by measuring ﬂuorescence at an excitation wavelength of
570 nm and an emission wavelength of 590 nm. All assays were
performed in duplicate with the observer blinded to the experi-
mental conditions. Cytotoxicity was expressed as percent survival
of control cultures incubated in the absence of peptide. Data are
expressed as mean ± S.E. Statistical analysis was assessed by un-
paired Student's t-test. A value of p < 0.05 was considered
signiﬁcant.
2.5. Leishmania amazonensis promastigote viability in culture
assay
Cell viability was evaluated in vitro by cultivating L. amazonensis
promastigotes (5  106 per well) in M199 medium (Sigma, MO,
USA), supplemented with 10% heat-inactivated fetal calf serum
(FCS; Invitrogen, CA, USA). Parasites were incubated with or
without peptides (1, 5, 10, 25, 50, 75 and 100 mM) at 25 C for 24 h.
Quantiﬁcation of viable cells was assessed either by cell counting or
by measuring the cleavage of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT; Sigma, MO, USA) as previ-
ously described (Zauli-Nascimento et al., 2010). MTT cleavage was
assessed in a microplate reader (POLARstar Omega, BMG Labtech,
Ortenberg, Germany) with a reference wavelength of 690 nm and a
test wavelength of 595 nm. Cytotoxicity was expressed as percent
survival of control cultures incubated in the absence of peptide.
Data are expressed as mean ± S.E. Statistical analysis was assessed
by unpaired Student's t-test. A value of p < 0.05 was considered
signiﬁcant.
2.6. Trypanosoma cruzi trypomastigote viability in culture assay
To validate the bioactivity of the peptides as anti-parasitic
treatment, we used a trypomastigote Y strain (2  106) that was
obtained from the 5th or 6th day of infection of cultures of the
Rhesus Monkey kidney epithelial line (LLC-MK2, ATCC, Boulevard
Manassas, VA, USA) (Andrews and Colli, 1982). The assay was car-
ried out in freshmodiﬁed Eagle's medium (MEM, Life Technologies,
NY, USA) phenol red-free with 2% fetal bovine serum (FBS, Wisent,
Montreal, QC) with or without peptides (1, 5, 10, 25, 50, 75 and
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measured by a colorimetric assay using 2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium
salt (WST-1) reagent according to manufacturer's instructions
(Roche, IN, USA) and measured at 450 nm, and expressed as a
percentage of control with no treatment. To corroborate the
viability assay, the disruption of the trypomastigotes (parasites)
motility was monitored by microscopic examination. Data are
expressed as mean ± S.E. Statistical analysis was assessed by un-
paired Student's t-test. A value of p < 0.05 was considered
signiﬁcant.2.7. Trypanosoma cruzi epimastigotes viability in culture assay
To validate the potential bioactivity of the peptides on T. cruzi
epimastigote forms, T. cruzi epimastigotes were axenically cultured
in liver infusion tryptose (LIT) media, supplemented with 10% fetal
bovine serum (FBS, Wisent, Montreal, QC). Parasites were pelleted
by centrifugation at 200  g for 10 min. Epimastigotes were
counted using a hemocytometer (Hausser Scientiﬁc, Horsham, PA,
USA) and seeded at a density of 1  107 parasites per well in LIT
media in sterile 96-well ﬂat-bottom plates (Becton Dickinson Fal-
con, Franklin Lakes, NJ, USA). Peptides (1, 5, 10, 25, 50, 75 and
100 mM)were added to eachwell. Plates were incubated at 27 C for
24 h. Live parasites were distinguished and counted using trypan
blue (Sigma, MO, USA). Percentage of inhibition is expressed as the
number of live parasites/total parasites  100. Data are expressed
as mean ± S.E. Statistical analysis was assessed by unpaired Stu-
dent's t-test. A value of p < 0.05 was considered signiﬁcant.2.8. Mammalian cell toxicity assay
To evaluate the toxicity of the peptides, Rhesus Monkey kidney
epithelial cells (LLC-MK2, ATCC, Boulevard Manassas, VA, USA)
were seeded in 96-well plates at a density of 8,000 cells/well 24 h
prior to treatments. All cell treatments were carried out in fresh
modiﬁed Eagle's medium (MEM, Life Technologies, NY, USA) me-
dium phenol red-free supplemented with 2% fetal bovine serum
(FBS, Wisent, Montreal, QC). The cells received four doses of pep-
tides (200 mMeach) at time-points of 0, 4, 8 and 12 h. After 24 h cell
infection was determined by the number of cells and parasites
using 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium monosodium salt (WST-1) reagent according to
manufacturer's instructions (Roche, IN, USA) measured at 450 nm,
and expressed as a percentage of control with no treatment. Cell
morphology was assessed by light microscopy. Data are expressed
as mean ± S.E. Statistical analysis was assessed by unpaired Stu-
dent's t-test. A value of p < 0.05 was considered signiﬁcant.2.9. In vivo peptide toxicity assay
BALB/c mice were treated with different peptides (or control,
eight mice per group) to assess their toxicity. All treatments were
performed between 9:00 a.m. and 4:00 p.m. by an experimenter
blinded to the treatment groups. BALB/c female mice (23e26 g, six
to eight weeks old), were housed in a temperature- and light-
controlled room for at least three days before use. All animals
were randomized and assigned to testing groups to generate bio-
logical replicates for each group.
Osmotic pumps (#2002, 0.5 ml/h, Alzet, CA, USA) ﬁlled with the
p4d (5 mg/kg/day) or vehicle were implanted subcutaneously on
the back of the mice following anesthesia using a standard surgical
procedure as recommended by the manufacturer.2.10. Trypanosoma cruzi in vivo assays
The study objective tested whether the peptides regulated the
level of parasitemia and survival in rodent models. BALB/c mice
were infected with T. cruzi and treated with different peptides (or
controls, ﬁve to eight mice per group), to assess their effect on
T. cruzi infection in vivo. The level of parasitemia was measured
every third day and survival was recorded.
Based on our experience, aminimum of ﬁve rodents per group is
required to obtain statistically meaningful data. An experimental
group size of ﬁve or more animals is necessary to achieve at least a
20% minimal difference in parasitemia and survival for a power of
95% with a <0.05 and b <20%. All treatments were performed be-
tween 9:00 a.m. and 4:00 p.m. by an experimenter blinded to the
treatment groups. BALB/c female mice (23e26 g, six to eight weeks
old), were housed in a temperature- and light-controlled room for
at least three days before use. All animals were randomized and
assigned to testing groups to generate biological replicates for each
group.
In the ﬁrst study, BALB/c mice (ﬁvemice per group) were treated
with peptides by intraperitoneal (ip) injection for 7 consecutive
days and after two days (day 10) given an additional injection for a
total of 8 injections of p4d (1.5 mg/kg/day) or vehicle. One day
before peptide treatment started, mice were infected with 500
bloodstream trypomastigotes (Strain H1 of T. cruzi) via ip injection.
In the second study osmotic pumps (#2002, 0.5 ml/h, Alzet, CA,
USA) ﬁlled with p4d (1.5 mg/kg/day) or vehicle were implanted
subcutaneously on the backs of the mice under anesthesia using a
standard surgical procedure as recommended by the manufacturer.
One day following pump implantation, mice were infected with
500 bloodstream trypomastigotes (Strain H1 of T. cruzi) via intra-
peritoneal injection. One group of control mice received Benzni-
dazole (Bz) (Sigma, MO, USA, 100 mg/kg/day) administered orally
for 20 days starting on day 1 post-infection.
2.11. Parasitemia level and mortality
Parasitemia in the blood was measured every third day in
infected mice by microscopic counting using a Neubauer chamber,
and survival was recorded daily for up to 24 days (ﬁrst study) or 50
days (second study) post-infection (Limon-Flores et al., 2010) with
the observer blinded to the experimental conditions.
2.12. T. cruzi parasite burden post mortem
Parasite burden was determined by quantitative real-time PCR
(qPCR) ampliﬁcation of T. cruzi DNA from cardiac biopsies (Quijano-
Hernandez et al., 2013). Brieﬂy, DNA was puriﬁed from cardiac bi-
opsies with QIAamp DNA Mini Kit (Qiagen, Limburg, Netherland)
following the manufacturer's instructions. A standard curve was
generated using mouse DNA spiked with known serial dilutions of
T. cruzi DNA. PCR reactions contained 50 ng of mouse DNA, 0.5 mM
primers TCZ-F 50-GCTCTTGCCCACAMGGGTGC-30 and TCZ-R 50-
CCAAGCAGCGGATAGTTCAGG-30, and 10 mL of EXPRESS SYBR
GreenER™ qPCR Supermix (Invitrogene, CA, USA) in a ﬁnal volume
of 20 mL. Reactions were run in triplicate on an Eco™ Real-Time PCR
System (Illumina, CA, USA) as follows: 50 C for 2 min and 40 cycles
of 95 C for 10 s, 55 C for 15 s and 72 C for 5 s. High-resolution
melting curves were determined at the end of the ampliﬁcation.
The standard curve had a slope of 3.127, R2 ¼ 0.9932 and an ef-
ﬁciency of 109%.
2.13. Statistical methods
Data are expressed as mean ± S.E. Statistical analysis was
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two-way measures analysis of variance (ANOVA) with post-hoc
testing by Tukey when appropriate. A value of p < 0.05 was
considered signiﬁcant. At least three independent experiments
were performed for each data set. Sample sizes for in culture ex-
periments were estimated based on previous experience of similar
assays and the effect size observed in preliminary experiments. No
samples were excluded from analysis. All samples were identical
prior to allocation of treatments and the observer was blinded to
the experimental conditions.
2.14. Animal care
Animal care and husbandry procedures were in accordancewith
established institutional and National Institutes of Health guide-
lines. The animal protocols were approved by the Ethical Com-
mittee of the Universidad Autonoma de Yucatan, Mexico, and by
the Stanford University Institutional Animal Care and Use
Committee.
2.15. Secondary structure studies, Raman experiments
In the Raman spectra, the shape of amide I and amide III bands
were analyzed to determine the secondary structure of the bio-
molecules. The shape of amide III band was evaluated qualitatively,
while the deconvolution of the amide I was performed as follows
(Maiti et al., 2004): 5 Lorentzian peaks for a-helix (1651 cm1), b-
sheet (1668 cm1), random coil (1683 cm1), tyrosine peak at
1620 cm1 and exponential baseline (represented with a broad
Lorentzian peak centered at 1500 cm1). Raman experiments were
performed with NTEGRA Spectra Raman spectrophotometer in-
strument, equipped with a peltier plate-cooled CCD camera in
backscattering geometry. The illumination source was a 473 nm
Cobolt Blues™ continuous wave diode-pumped solid state laser
brought to the sample by a Mitutoyo long working distance
objective (100, 0.7 NA). Laser power at sample was 2 mW, as
measured by Coherent LaserCheck™. Samples were measured in
dry state. Spectra from dry samples were acquired in 1 min in-
crements for 10 min total. The absence of sample degradation was
conﬁrmed by absence of any difference between the 1-min spectra,
besides minimal changes in ﬂuorescence baseline signal.
3. Results
3.1. Rational design of peptides with anti-parasitic activity derived
from LACK and TRACK
We hypothesized that short sequences in the scaffold proteins
LACK and TRACK that are conserved among parasite strains and
species, but are not conserved in the mammalian RACK, may
mediate interactions important to the parasites but not to the
mammalian host. We focused on LACK in Leishmania and compared
it to RACK, the ortholog inmammalian hosts (Fig.1). Although LACK
is similar (>75% similar and 48% identical) to RACK, at least eight
distinct regions in LACK differ substantially (57% similarity and
30% identity to RACK; Fig. 1A; these regions are designated as L1
to L8). Importantly, these eight regions in LACK are conserved be-
tween different species of Leishmania (Supplementary Figure 1),
suggesting that theymay be functionally important for the parasite.
Most of the non-conserved regions between RACK and LACK are
also less conserved between RACK and TRACK (Supplementary
Figure 2) and are conserved between different Trypanosoma spe-
cies (Supplementary Figure 3). We hypothesized that peptides
derived from these parasite-unique regionsmay have anti-parasitic
activity without affecting mammalian host signaling. Wesynthesized peptides (p1-p8) derived from regions L1-L8 in LACK
(Supplementary Figure 4-5 and Table 1) and tested them for their
bioactivity towards parasites.
We also covalently linked the peptides to a cell-penetrating
peptide (CPP), which allows the peptides to cross cell membranes
(Lonn and Dowdy, 2015). Peptides conjugated to CPP have previ-
ously been delivered intracellularly to the parasites Leishmania and
Plasmodium (the parasite causing malaria), where they inhibit in-
fections (Corradin et al., 2002; Dhawan et al., 2003). Speciﬁcally, we
used TAT47-57 (YGRKKRRQRRR, Supplementary Figure 4), which has
been shown to deliver macromolecules into cells in cell culture and
in animal disease models in vivo, and which has been used in over
25 clinical trials (Lonn and Dowdy, 2015).
3.2. LACK-derived peptides show anti-parasitic activity
Treatment of L. donovani promastigotes with peptide p4a (see
Supplemental Table 1 for sequence information) reduced the
parasite viability in culture by 60% at 48 h (Fig. 2A, left panel; IC50
~40 mM, Fig. 2B, dashed lines), and p3 treatment resulted in ~50%
reduction of parasite viability (Fig. 2A). None of the other targeted
peptides had any effect on L. donovani promastigote viability. In
addition, treatment with p4a reduced the viability of L. amazonensis
promastigotes in culture by ~100% after 24 h (IC50 ~23 mM, Fig. 2B,
solid lines). TAT peptide alone and p4, which lacks TAT
(Supplemental Table 1), showed no anti-parasitic activity
(Fig. 2AeB), demonstrating that TAT is not cytotoxic and that
intracellular delivery by TAT is required for the anti-parasitic effect
of the cargo.
The L4 region in LACK has 88% similarity to TRACK (Fig. 2C).
Treatment of T. cruzi trypomastigotes in culture with the LACK-
derived peptide, p4a, reduced the viability of the parasites by
~75% compared with control (Fig. 2A, right panel; IC50 ~20 mM,
Fig. 2D). Again, the TAT or p4 alone showed no anti-parasitic ac-
tivity (Fig. 2A, D).
3.3. Structureeactivity relationship studies of p4a
We tested the effect of the relative positions of the cargo (p4)
and the carrier (TAT), and the effect of different linkers between the
carrier and the cargo on the leishmanicidal (L. donovani) and try-
panocidal (T. cruzi epimastigotes) activity (Fig. 3B and
Supplementary Figure 5 show peptide structures). When the cargo
was linked at the C-terminus of TAT by a ﬂexible GG linker (p4b,
Supplemental Table 1 and Fig. 3B), the anti-parasitic effect was
completely lost relative to a peptide with the same linker and the
cargo at the N-terminus (p4a vs. p4b; Fig. 3A). In contrast, when the
cargo was linked at the TAT C-terminus using a constrained gamma
amino butyric acid (GABA; p4c) linker, the anti-parasitic activity
was comparable to that observed in the reverse order using the
ﬂexible GG linker (p4a; Fig. 3A).
Conformational constraints such as cyclization usually decrease
degradation and increase bioactivity of peptides, as compared with
their linear counterparts (Qvit et al., 2008; Qvit and Crapster, 2014;
Qvit and Kornfeld, 2016). Therefore, we developed two cyclic
peptides and tested their activity in the same assay. One of the two
cyclic peptides, p4d, was more active than the linear peptide, p4a,
reducing parasite viability to only ~5% as compared with control
(Fig. 3A). The IC50 of p4d was 4e5 fold lower than the IC50 of p4a
(IC50 ~6 mM and IC50 ~3 mM for L. donovani and T. cruzi epi-
mastigotes, respectively, Fig. 3C; vs. IC50 of ~20 mM for both by p4a,
Fig. 2B, D). Importantly, the peptides derived from the L4 region did
not affect the viability of naive LLC-MK2, Rhesus monkey kidney
cells, conﬁrming that the peptides are not toxic to the mammalian
host cells (Fig. 3D).
Fig. 1. Rational design of peptides with anti-parasitic activity. Sequence alignment between human RACK (P63244) and L. donovani LACK (Q76LS6). (A) The alignment identiﬁed
eight short regions labeled L1-L8 of low similarity between LACK and RACK. The alignment between the proteins was done using the FASTA server, where: (:) represents identical
amino acids, and (.) represents similar amino acids. (B) The position of identiﬁed L regions in A are highlighted in the structure of the Trypanosoma LACK homolog, TRACK (PDB:
4V8M) and colored as in A. We used the TRACK structure because the structure of LACK is not available and there is high similarity between LACK and TRACK (over 75% similarity).
The sequence of the L4 region in LACK is also provided on the structure.
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increased activity of the cyclic peptide is due to its improved
resistance to degradation. The linear peptide p4a was less stable
(>55% degradation by trypsin occurred in <20 min, Fig. 4AeB) than
the cyclic peptide p4d (<20% trypsin cleavage in 6 h, Fig. 4CeD). The
increased stability may account for the superior anti-parasitic ac-
tivity of the cyclic peptide compared to the linear peptide. Impor-
tantly, despite the increased constraint in p4d relative to p4a,
analysis of the secondary structure of these peptides using Raman
spectroscopy showed that their structures were very similar
(Supplementary Figure 6). Amide III regions did not exhibit a pro-
nounced peak, suggesting that the majority of the structure was
disordered for all three molecules. The amide I peak showed a
mixture of b-sheet and unordered secondary structures. The p4a
and p4d molecules showed a higher percentage of ordered struc-
ture, mostly due to an increase in a-helix content. In the ﬁgure, the
height of the tyrosine peak is compared to the height of the amide I
band (pairs of horizontal dashed lines). It can also be seen that the
ratio of the intensities of Tyr and amide band slightly increases as
follows: TAT < p4a < p4d, which is due to an increase in the number
of amide bonds per molecule. This proves that the measured con-
formations come mostly from the cargo amino acids and not solely
the carrier.
Structureeactivity relationship (SAR) studies on the cargo of thecyclic peptide helped determine which amino acids in the peptide
are required for bioactivity. Alanine scanning of the cyclic peptide
p4d demonstrated that substitution of any of the amino acids from
the N-terminal half (R, N, G, or Q) with alanine (A) only slightly
reduced the anti-parasitic activity of the peptide. However, sub-
stitution of any one of the amino acids in the C-terminal half (C, Q, R
or K) caused a reduction or a complete loss of anti-parasitic activity,
indicating that the C-terminal half of the peptide is required for this
activity (Fig. 5A). Interestingly, the same C-terminal half is the most
highly conserved in the L4 region between LACK and TRACK
(Fig. 5B), which may explain why the L4 region-derived peptide
(from LACK) had both leishmanicidal and trypanocidal activity.3.4. p4d decreases parasite burden in mice infected with T. cruzi
We performed two preliminary studies to evaluate the effect of
the peptides in mice infected with T. cruzi. The ﬁrst study was
designed as a fast screen (24 days). BALB/c mice (ﬁve females per
group) were infected with trypomastigotes (T. cruzi) via intraperi-
toneal (ip) injection, and on the following day we began the peptide
treatment. Micewere treatedwith 8 ip injections of p4d (1.5mg/kg/
day) or vehicle. Treatment with p4d reduced the parasitemia by
85% (day 7) and 80% of the mice survive compared to none of the
vehicle treated mice (day 24) (Supplementary Figure 7). Next we
Fig. 2. Leishmanicidal and trypanocidal activity of peptides in culture. Peptides were added to L. donovani promastigotes as a single addition in DMEM media, or to trypomastigote
forms of T. cruzi cultured in LLC-MK2 Rhesus monkey kidney epithelial cells, and their leishmanicidal and trypanocidal activity was evaluated after 48 or 24 h, respectively. See
Materials &Methods sections 2.5 and 2.7 for more experimental details. (A) Anti-parasitic activity was assessed with various peptides derived from various domains in LACK, p1-p8,
and conjugated to TAT carrier (TAT47-57 (Rizzuti et al., 2015)) (given once, at 100 mM, each, red - leishmanicidal activity and blue - trypanocidal activity). Only p3 and p4a had
leishmanicidal activity (Left panel). p4a also had high trypanocidal activity (Right panel). (B) Dose-response curve of p4a against L. donovani promastigotes (48 h) and L. amazonensis
promastigotes (24 h). p4a had leishmanicidal activity [IC50 ~40 mM (dash lines) and IC50 ~23 mM (solid lines) against L. donovani promastigotes and L. amazonensis promastigotes,
respectively]. (C) Sequence alignment of L4 region between L. donovani LACK (Q76LS6) and T. cruzi TRACK (Q4DTN2). L4 region is 50% identical and 88% similar between LACK and
TRACK, where: (:) represents identical amino acids, and (.) represents similar amino acids. (D) Dose-response curve of p4a, p5 and TAT activity against T. cruzi. p4a had trypanocidal
activity (IC50 ~20 mM against T. cruzi, 24 h). Data are from three experiments expressed as mean ± SEM, and the differences in susceptibility were statistically signiﬁcant (xp < 0.01,
#p < 0.05 and *p < 0.001 vs. TAT), as assessed by Student's t test. The observer was blinded to the experimental conditions. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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lowed the mice for 50 days. Mice were infected with trypomasti-
gotes (T. cruzi) via ip injection and were treated with p4d or vehicle
for the ﬁrst 14 days after infection at 1.5 mg/kg/day, using osmotic
pumps, which provide slow and sustained delivery of the peptide.
In this study, p4d decreased parasitemia by more than 75% (days
39e42) (Fig. 6A). The treatment also increased host survival by over
three-fold (Fig. 6B), and reduced parasite burden in cardiac tissue
by three-fold (Fig. 6C).
We performed an additional animal study to evaluate the
toxicity of p4d. Osmotic pumpswere used to deliver p4d for 28 days
at 5 mg/kg/day, a 3.3 fold higher dose than in the anti-parasitic
study, above. The effect of the prolonged treatment on mice was
compared to that of vehicle-treated mice (eight BALB/c females per
group). The peptide did not show any toxic effects (there was no
weight difference, induction of seizures, strange behavioral or
metabolic disorders in the p4d relative to vehicle-treated mice)
when the naive uninfected mice were treated with >3 the dose
for twice the duration as the infected mice.
In conclusion, in both animal parasite models, p4d reduced the
level of parasitemia by >65%, increased the survival by at least
three-fold, and decreased the parasite burden on the peak days. In
the second study (50 days) one control group was treated with
Benznidazole (Bz) (Fig. 6A) for a longer duration than the peptide
(21 days vs. 14 days, respectively) and with much higher dose
(100 mg/kg/day vs. 1.5 mg/kg/day, respectively; moreover since themolecular weight of Benznidazole is less than 10% of p4d (216.25 g/
mol vs. 2854.32 g/mol, the mole ratio between Benznidazole and
p4d is 920:1 (0.46 mmol vs. 0.0005 mmol)). In this group para-
sitemiawas undetectable and all themice survived the study. These
combined data conﬁrm the cell culture data and suggest that
further optimization of peptide sequence, formulation, dose, and
route of administration should achieve higher efﬁcacy in vivo.4. Discussion
Neglected tropical diseases, endemic in developing regions of
the world, are responsible for signiﬁcant morbidity among low-
income populations (Hotez et al., 2007). Most current treatments
for these diseases are toxic and are limited by drug resistance.
Toxicity occurs because most drugs are relatively non-selective
toxins with more generalized mechanisms of action affecting
both parasite and host. Many drugs are directed to the catalytic site
of enzymes such as proteases, kinases, and metabolic enzymes
((Olin-Sandoval et al., 2010); for review (Qvit and Crapster, 2014;
Renslo and McKerrow, 2006)). Although there has been some
success using this approach for the treatment of Chagas' disease,
such as K777 (an a-ketone irreversible cruzipain inhibitor) (Barr
et al., 2005), these catalytic sites are usually highly conserved be-
tween the parasites and mammalian hosts, and therefore it is
challenging to speciﬁcally target the parasite (Seebeck et al., 2011).
The other limitation of current treatments relates to drug
Fig. 3. Structure activity relationship (SAR): Studies of the linker and cyclization of the peptides in culture. Peptides were added once to L. donovani promastigotes or to epi-
mastigote forms of T. cruzi, and their leishmanicidal and trypanocidal activity was evaluated after 48 or 24 h, respectively. See Materials & Methods Sections 2.5 and 2.7 for more
experimental details. (A) Anti-parasitic activity was assessed with various peptide analogs having modiﬁed linkers between the cargo and the TAT carrier (TAT47-57 (Rizzuti et al.,
2015)) and changing the position of the TAT carrier relative to the cargo, as well as p4a analogs having conformational constraints (given once, at 100 mM, each, red - leishmanicidal
activity and blue - trypanocidal activity). (B) Peptides schematic structure. The peptides are comprised of TAT47-57 (Rizzuti et al., 2015) (green); linker (light brown), one or two
amino acids used as linker between TAT and the cargo; and p4, the cargo (blue). Cyclic peptide analogs with conformational constraints of p4 were prepared; these analogs have the
same amino acids as the linear analog and an extra alkyl chain (grey). (C) Dose-response curve of p4d against Leishmania (red) and T. cruzi (blue) parasites. p4d has leishmanicidal
(Leishmania donovani) and trypanocidal (T. cruzi epimastigotes) activity was evaluated after 48 or 24 h, respectively. (IC50 ~6 mM and IC50 ~3 mM, respectively). (D) Incubation with
the p4 analogous peptides did not affect the viability of naive (non-infected) LLC-MK2 cells, indicating that the peptides are not toxic to the mammalian host (100 mM, delivered 4
times over 24 h). The observer was blinded to the experimental conditions. Data are representative of three independent experiments and presented as mean ± SEM. Statistical
analysis was performed using two-tailed unpaired Student's t-test (xp < 0.01, #p < 0.05, *p < 0.001 vs. TAT; ^p < 0.05 vs. the linear peptide, p4a). (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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(i.e., early or inconsistent treatment) may enable development of
mutations in the drug target. We have described here a simple and
fast approach to identify an anti-parasitic peptide that may over-
come the limitations of current treatments in the following ways:
(1) Our candidate should have less or no toxicity, because it spe-
ciﬁcally targets protein domains that are unique to the parasite, not
the host; (2) This approach reduces the probability that resistance
will arise because substitution mutations in the parasites are much
less likely to occur at evolutionarily conserved sites in proteins
(Thomas et al., 2003).
We focused our drug discovery efforts on the parasite-speciﬁc
scaffold proteins, LACK and TRACK, which are essential for the
survival and infectivity of both Leishmania sp. and T. cruzi, respec-
tively (Mougneau et al., 1995; Rothberg et al., 2006; Choudhury
et al., 2011). Our rational approach identiﬁed an inhibitor which
inhibited parasites’ growth in culture and in vivo without exerting
toxic effects. We show that peptides corresponding to the L4 region
from LACK, which is only ~20% identical to mammalian RACK
(Fig. 1), had anti-parasitic activity against both Leishmania sp. and
T. cruzi in culture and showed anti-trypanosomal activity in vivo.
Two different animal models were used in these latter studies: a
short study (24 days) in which the peptide was delivered by ip
injection and a longer study (50 days), in which the peptide was
delivered in a sustained fashion, using subcutaneous osmotic
pumps. Osmotic pumps permit continuous administration of shorthalf-life molecules and are gaining widespread use for targeting
parasites (Shibata et al., 2011). In both studies, the peptide treat-
ment was for a short time (only one-third of the study) and in a low
dose (1.5 mg/kg/day). Nevertheless, in these two studies p4d
demonstrated promising anti-parasitic activity. The peptide was
conjugated to TAT, which is used to deliver large macromolecules
and peptides into cells. Furthermore, it was recently shown that
whenmiltefosine, an oral anti-parasitic drug, was linked to TAT, the
resulting compound was efﬁciently internalized into a miltefosine-
invulnerable Leishmania strain, resulting in fast parasite killing, and
successful avoidance of resistance (de la Torre et al., 2014). There-
fore, TAT is a proven tool to improve drug intake and treatment
efﬁcacy in the parasite. Optimized peptoid delivery using a sub-
cutaneous deposit (single injection) or a sustained delivery
employing a subcutaneous osmatic pump (similar to that used for
yearly contraceptive delivery in some developing countries) could
ensure effective delivery and compliance to drug treatment in
humans, especially in rural areas, and therefore decrease the
chance of resistance emerging.
Although the biology of T. cruzi and Leishmania is signiﬁcantly
different, it has already been shown that targeting either unique
parasite proteins or exclusive domains on scaffold proteins can be a
successful approach for the development of anti-parasite agents;
inhibitors targeting several key proteins, such as polyamine
biosynthetic enzymes (Heby et al., 2007), trypanothione reductase
(Parveen et al., 2005), sterol 24-methyltransferase (Magaraci et al.,
Fig. 4. Stability studies of the native p4a peptide and the cyclic peptide, p4d. Stability of peptides against proteolytic digestions as determined by HPLC analysis using trypsin (for
more experimental details, see Section 2.3 Peptide stability). (AeB) Over 55% degradation of the linear peptide, p4a, occurred in less than 20 min (CeD) Proteolytic cleavage of the
cyclic peptide (p4d) was much slower, with <20% of the cyclic peptide cleaved in 6 h. The cyclic peptide, p4d, was found to be signiﬁcantly more stable than the linear peptide, p4a.
Fig. 5. Structure activity relationship (SAR) studies: Alanine scan of the cyclic peptide in culture. Peptides were added once to L. donovani promastigotes or to epimastigote forms of
T. cruzi and their leishmanicidal and trypanocidal activity was evaluated after 48 or 24 h, respectively. (A) Alanine scan of p4d. Anti-parasitic activity was assessed after treatment
with p4d and alanine-scan analogs (given once, at 100 mM). Substitution of the amino acids from the N-terminal (R, N, G, or Q) only slightly reduced the anti-parasitic activity of the
peptide. Though, substitution of any one of the amino acids in the C-terminal half (C, Q, R or K) caused a reduction or a complete loss of anti-parasitic activity. (B) Sequence
alignment of L04 region between L. donovani LACK (Q76LS6) and T. cruzi TRACK (Q4DTN2). L4 region is 50% identical and 88% similar between LACK and TRACK, where: (:) rep-
resents identical amino acids, and (.) represents similar amino acids. Data are representative of three independent experiments and presented as mean ± SEM. Statistical analysis
was performed using two-tailed unpaired Student's t-test (#p < 0.05, *p < 0.001 vs. TAT). The observer was blinded to the experimental conditions.
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that peptides derived from the L4 region of RACK exhibit both anti-
leishmanial and anti-trypanosomal effects, SAR studiesdemonstrated that amino acids found to be critical for the bioac-
tivity were those conserved between LACK and TRACK. Further
studies exploring the bioactivity of L4 region-derived peptoids
Fig. 6. The effect of p4d on T. cruzi infections in vivo. T. cruzi parasitemia level, mortality, and parasite burden in infected mice (see Materials and Methods for more experimental
details). Mice treated with the cyclic peptide, p4d, showed a 65% reduction in parasitemia (A), increase in survival by three-fold (B) and signiﬁcantly less parasite burden of
amastigotes in the cardiac muscle at the peak days (days 39e42) (C). The observer was blinded to the experimental conditions. Data presented as mean ± SEM. Statistical analysis
was performed using two-tailed unpaired Student's t-test (xp < 0.01, #p < 0.05, *p < 0.001 vs. control).
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peptides derived from TRACK, are now under evaluation. In addi-
tion, the cysteine from the L4 region of LACK is conserved in most
Leishmania species as well as between LACK and TRACK. However,
because it can be susceptible to rapid oxidation, the anti-parasitic
activity of substituting the cysteine with serine, methionine, etc,
will be valuable. Moreover, additional considerations should be
given to the difference in the biology of each parasite in future
optimization studies of this lead peptide, p4d. While T. cruzi divides
within the cytoplasm, Leishmania divides within the phag-
olysosome, and therefore peptides targeting Leishmania need to
cross more membranes and act within the acidic environment of
the phagolysosome.
Importantly, although peptides that work intracellularly are not
traditionally considered to be suitable drugs, this notion is now
being challenged in general (Fosgerau and Hoffmann, 2015) and
also for anti-parasite agents (Qvit and Crapster, 2014). Previously,
we have shown that peptide inhibitors can be useful pharmaco-
logical agents. For example, we have used peptide inhibitors of
RACK in animal models of heart failure (Mochly-Rosen et al., 2012)
andmyocardial infarction (Inagaki et al., 2003) as well as in patients
(Bates et al., 2008). Although the optimal treatment regimen and
dose have not yet been determined, our data suggest that peptoids
(modiﬁed peptides) derived from the L4 region of LACK, which will
be highly speciﬁc and effective, will fulﬁll the target product proﬁle
published by DNDi (http://www.dndi.org/diseases-projects/
diseases/chagas/target-product-proﬁle.html and http://www.dndi.
org/diseases-projects/diseases/vl/tpp/tpp-vl.html), and therefore
will be promising candidates as anti-parasitic lead compounds. In
addition, the possibility to combine the peptide lead compound
that we identiﬁed with other chemotherapy is a valuable option. It
may be most effective to try combination with current drugs that
have different mechanisms of action, for example benznidazole;
such a combination may reduce the potential for resistance as well
as decrease the required quantity of benznidazole, thereby
reducing toxicity.
Moreover, topical formulations offer several advantages over
systemic delivery, including easier administration, minimizing
adverse effects and reducing cost (Garnier and Croft, 2002; Moreno
et al., 2014). One approach may be to use the peptides as topical
treatment for localized CL.
The rational method that we used here to identify an effective
drug lead is rapid, does not require high throughput screens or
extensivemedicinal chemistry efforts, and uses very limited capital.
We suggest that this approach to generate inhibitors is likelygeneralizable and can be adapted for the design of other novel
drugs.
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